Humacyte, Inc. (HUMA)
(Delayed Data from NSDQ)
$8.25 USD
-0.37 (-4.29%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $8.33 +0.08 (0.97%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Humacyte, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -110.78 | -11.97 | -26.48 | -0.23 | NA |
Depreciation/Amortization & Depletion | 8.20 | 9.76 | 9.22 | 0.00 | NA |
Net Change from Assets/Liabilities | 6.57 | 1.03 | -0.56 | 0.00 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 22.70 | -69.95 | -63.37 | -0.02 | NA |
Net Cash From Operating Activities | -73.31 | -71.13 | -81.19 | -0.25 | NA |
Property & Equipment | -2.28 | -1.05 | -0.22 | 0.00 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 2.11 | 5.89 | -8.00 | -100.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | -0.17 | 4.85 | -8.22 | -100.00 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.57 | 0.54 | 0.60 | 101.58 | NA |
Issuance (Repayment) of Debt | 5.62 | -1.98 | 27.93 | 0.10 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -1.68 | 0.00 | 238.46 | -0.33 | NA |
Net Cash from Financing Activities | 4.51 | -1.45 | 266.98 | 101.34 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -68.97 | -67.73 | 177.57 | 1.09 | NA |
Cash at Beginning of Period | 149.77 | 217.50 | 39.93 | 0.00 | NA |
Cash at End of Period | 80.80 | 149.77 | 217.50 | 1.09 | NA |
Diluted Net EPS | -1.07 | -0.12 | -0.66 | -0.08 | NA |
Fiscal Year End for Humacyte, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -31.90 | -110.78 | -85.67 | -59.68 |
Depreciation/Amortization & Depletion | NA | 1.79 | 8.20 | 6.37 | 4.54 |
Net Change from Assets/Liabilities | NA | -4.66 | 6.57 | 3.44 | -3.61 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 7.42 | 22.70 | 21.61 | 17.50 |
Net Cash From Operating Activities | NA | -27.35 | -73.31 | -54.25 | -41.24 |
Property & Equipment | NA | -0.39 | -2.28 | -2.13 | -1.64 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 2.11 | 2.11 | 2.11 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.39 | -0.17 | -0.02 | 0.47 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 43.40 | 0.57 | 0.31 | 0.21 |
Issuance (Repayment) of Debt | NA | 19.40 | 5.62 | 6.21 | 6.79 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | -1.68 | -1.68 | -1.39 |
Net Cash from Financing Activities | NA | 62.80 | 4.51 | 4.84 | 5.61 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 35.06 | -68.97 | -49.43 | -35.17 |
Cash at Beginning of Period | NA | 80.80 | 149.77 | 149.77 | 149.77 |
Cash at End of Period | NA | 115.86 | 80.80 | 100.34 | 114.60 |
Diluted Net EPS | NA | -0.29 | -0.24 | -0.25 | -0.22 |